EcoDrugPlus

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSMPUG00000005525
Gene Symbol: EGLN1
1 Cross references
229 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSMPUG00000017671
Gene Symbol: EGLN2
2 Cross references
190 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSMPUG00000001043
Gene Symbol: EGLN3
2 Cross references
207 Possible Orthologues:

Elastase, Neutrophil Expressed

Ensembl ID : ENSMPUG00000009405
Gene Symbol: ELANE
2 Cross references
102 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSMPUG00000012019
Gene Symbol: EPAS1
2 Cross references
222 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSMPUG00000016062
Gene Symbol: ECE1
2 Cross references
229 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSMPUG00000006985
Gene Symbol: EDNRA
2 Cross references
265 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSMPUG00000003329
Gene Symbol: EDNRB
2 Cross references
264 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSMPUG00000007249
Gene Symbol: EZH2
2 Cross references
222 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSMPUG00000018153
Gene Symbol: EGFR
2 Cross references
285 Possible Orthologues:

Epoxide Hydrolase 2

Ensembl ID : ENSMPUG00000000882
Gene Symbol: EPHX2
2 Cross references
203 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSMPUG00000014982
Gene Symbol: ERBB2
2 Cross references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).